|
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
RECRUITINGSponsored by H. Lee Moffitt Cancer Center and Research Institute
Actively Recruiting
SponsorH. Lee Moffitt Cancer Center and Research Institute
Started2020-05-05
Est. completion2028-03
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT04343365
Summary
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care. * Participant must have a life expectancy greater than 3 months * Participant must have an ECOG performance status 0-2 * Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB * Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling. Exclusion Criteria: * None
Conditions2
CancerIncurable Disease
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorH. Lee Moffitt Cancer Center and Research Institute
Started2020-05-05
Est. completion2028-03
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT04343365